Given the historical exclusion of women from clinical trials and social attitudes about female sexual desire, it’s easy to assume that no Viagra-like drug is available for women because women’s sexual pleasure is not taken seriously enough to develop one. The reality, though, is more complicated than a case of gender bias. Last month, the U.S. Food and Drug Administration (FDA) held a public meeting and scientific workshop (fully available online) on female sexual dysfunction (FSD) and available therapies as part of its “patient-focused drug development” series. The workshop followed up on the FDA’s rejection of flibanserin, a proposed drug to treat FSD. The drug was rejected in 2010, and again in 2013, with the FDA telling the drug maker, Sprout Pharmaceuticals,